Association study of PCSK9 SNPs (rs505151 & rs562556) and their haplotypes with CVDs in Indian population

Association study of PCSK9 SNPs (rs505151 & rs562556) and their haplotypes with CVDs in Indian population

Background Cardiovascular disease (CVD) has emerged as the most prevalent cause of death in India. Pro-protein Convertase Subtilisin/Kexin Type 9 (PCSK9) gene has been found to be associated with lipid levels and a biomarker for susceptibility of CVD. Aim To study the association of PCSK9 SNPs rs505...

Full description

Bibliographic Details
Main Authors:	Kiran Devi, Archna Bhargave, Imteyaz Ahmad, Anita Yadav, Ranjan Gupta
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-01-01
Series:	Annals of Human Biology
Subjects:	cvd (cardiovascular disease) pcsk9 snp (single nucleotide polymorphism) low-density lipoprotein tc (total cholesterol)
Online Access:	http://dx.doi.org/10.1080/03014460.2023.2171121

Similar Items

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
by: Jia X, et al.
Published: (2022-07-01)

The Concentration of PCSK9-Lp(a) Complexes and the Level of Blood Monocytes in Males with Coronary Atherosclerosis
by: Anastasiia Yu. Filatova, et al.
Published: (2023-06-01)

A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants
by: Kepa B. Uribe, et al.
Published: (2021-12-01)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
by: Yara Azar, et al.
Published: (2022-05-01)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
by: Christopher LaFratte, et al.
Published: (2023-09-01)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
by: Tina Levstek, et al.
Published: (2023-03-01)

Polymorphic Variant rs11206510 in PCSK9 and Risk of Coronary Artery Disease in Bulgarians
by: Tzveova R., et al.
Published: (2023-04-01)

RETRACTED ARTICLE: Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-12-01)

Increased Circulating Levels of PCSK9 and Pro-Atherogenic Lipoprotein Profile in Pregnant Women with Maternal Supraphysiological Hypercholesterolemia
by: Claudette Cantin, et al.
Published: (2022-04-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

DNMT1 SNPs (rs2114724 and rs2228611) associated with positive symptoms in Chinese patients with schizophrenia
by: Junjiao Ping, et al.
Published: (2023-10-01)

Targeting Allosteric Site of PCSK9 Enzyme for the Identification of Small Molecule Inhibitors: An In Silico Drug Repurposing Study
by: Nitin Bharat Charbe, et al.
Published: (2024-01-01)

A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo
by: Alexandra K. Suchowerska, et al.
Published: (2022-11-01)

Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats
by: Hui-Chun Huang, et al.
Published: (2022-07-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo
by: Elise F. Villard, PhD, et al.
Published: (2016-10-01)

PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
by: Sai Sahana Sundararaman, et al.
Published: (2021-07-01)

Insight into the Evolving Role of PCSK9
by: Mateusz Maligłówka, et al.
Published: (2022-03-01)

PCSK9 is not secreted from mature differentiated intestinal cells
by: Moreau François, et al.
Published: (2021-01-01)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023-12-01)

Impact of bariatric surgery on circulating PCSK9 levels as a marker of cardiovascular disease risk: a meta-analysis
by: Tannaz Jamialahmadi, et al.
Published: (2022-08-01)

The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
by: Fengyuan Lu, et al.
Published: (2023-09-01)

Failure of lipid control by PCSK9 inhibitors in compound heterozygous familial hypercholesterolemia complicated with premature myocardial infarction: A case report
by: Ziyue Zhang, et al.
Published: (2024-03-01)

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
by: Minglu Ma, et al.
Published: (2023-03-01)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with PCSK9/LDLR pathway.
by: Sarina Ataei, et al.
Published: (2023-01-01)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
by: Rahayu Zulkapli, et al.
Published: (2023-03-01)

SNP polymorphism rs80867243, rs81379421 and rs81236069 in pigs of maternal breeds
by: L. V. Getmantseva, et al.
Published: (2018-08-01)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

Association of <i>PCSK1</i> and <i>PPARG1</i> Allelic Variants with Obesity and Metabolic Syndrome in Mexican Adults
by: Jorge Velazquez-Roman, et al.
Published: (2023-09-01)

Exploring PCSK9 Genetic Impact on Lipoprotein(a) via Dual Approaches: Association and Mendelian Randomization
by: Ya-Ching Chang, et al.
Published: (2023-09-01)

Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome
by: Satoshi Yamashita, et al.
Published: (2023-05-01)

PCSK9 Associated Promoter Methylation Status in Patients with Hyperlipidemia
by: Samaneh Bahrami, et al.
Published: (2021-08-01)

Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors
by: Katja Hrovat, et al.
Published: (2022-07-01)

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
by: Hongzhen Chen, et al.
Published: (2023-05-01)

Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab
by: Federica Fogacci, et al.
Published: (2023-12-01)

PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs
by: Nikolay Kuzmich, et al.
Published: (2022-01-01)

Koroner Kalp Hastalarında PCSK9 E670G ve N425S Gen Varyasyonlarının Etkisinin Türk Toplumunda Değerlendirilmesi
by: Hülya Yılmaz Aydoğan, et al.
Published: (2018-04-01)

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
by: Konstantinos Koskinas, et al.
Published: (2016-07-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01)

Evaluation of cardiovascular diseases risk calculators for CVDs prevention and management: scoping review
by: Mohammed Abd ElFattah Mohammed Darwesh Badawy, et al.
Published: (2022-09-01)